Arctic Bioscience AS

Symbol: ABS.OL




Market price today

  • 0.0000

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 253.70M

    MRK Cap

  • 0.00%

    DIV Yield

Arctic Bioscience AS (ABS-OL) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Christer L. Valderhaug
Full-time employees:17
Address:Industrivegen 42

Arctic Bioscience AS, a biotechnology company, develops and commercializes pharmaceutical and nutraceutical products. Its development stage product candidate is HRO350, a novel oral treatment for mild-to-moderate psoriasis. The company sells its nutraceuticals as bulk ingredients to other companies under the ROMEGA brand worldwide. Arctic Bioscience AS was incorporated in 2011 and is based in Ørsta, Norway.

General Outlook

In simple terms, Arctic Bioscience AS has 25.37 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.154% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.154%. This means they run their business efficiently.

Return on Investments

Furthermore, the proficiency of Arctic Bioscience AS in capital utilization is underscored by a remarkable 0.005% return on capital employed.

Stock Prices

Arctic Bioscience AS's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $10.45, while its low point bottomed out at $9.5. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Arctic Bioscience AS's stock market.

Liquidity Ratios

Analyzing ABS.OL liquidity ratios reveals its financial health of the firm. The current ratio of 335.86% gauges short-term asset coverage for liabilities. The quick ratio (197.93%) assesses immediate liquidity, while the cash ratio (197.93%) indicates cash reserves.

Current Ratio335.86%
Quick Ratio197.93%
Cash Ratio197.93%

Profitability Ratios

Lastly, with an EBIT per revenue ratio of 15.38%, we grasp its operational profitability.

EBIT per Revenue15.38%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.36, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding198
Days of Inventory Outstanding1814
Operating Cycle1813.60
Days of Payables Outstanding1016
Cash Conversion Cycle797
Payables Turnover0.36
Inventory Turnover0.20
Fixed Asset Turnover0.30
Asset Turnover0.03

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.86%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.02, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.79%, and total debt to capitalization, 2.11%, ratios shed light on its capital structure.

Debt Ratio1.86%
Debt Equity Ratio0.02
Long Term Debt to Capitalization0.79%
Total Debt to Capitalization2.11%
Company Equity Multiplier1.16

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.33, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.79, reflects the portion of profit attributed to each share. The book value per share, 10.19, represents the net asset value distributed per share, while the tangible book value per share, 4.65, excludes intangible assets.

Revenue Per Share1.33
Net Income Per Share-1.79
Book Value Per Share10.19
Tangible Book Value Per Share4.65
Shareholders Equity Per Share10.19
Interest Debt Per Share0.26
Capex Per Share-1.79

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -1.52%, indicates top-line expansion, while the gross profit growth, -517.23%, reveals profitability trends. EBIT growth, -29.95%, and operating income growth, -29.95%, offer insights into operational profitability progression. The net income growth, -33.77%, showcases bottom-line expansion, and the EPS growth, -27.86%, measures the growth in earnings per share.

Revenue Growth-1.52%
Gross Profit Growth-517.23%
EBIT Growth-29.95%
Operating Income Growth-29.95%
Net Income Growth-33.77%
EPS Growth-27.86%
EPS Diluted Growth-27.86%
Weighted Average Shares Growth4.08%
Weighted Average Shares Diluted Growth4.08%
Operating Cash Flow Growth-58.64%
Free Cash Flow Growth-1.98%
10-Year Revenue Growth per Share30.09%
5-Year Revenue Growth per Share30.09%
3-Year Revenue Growth per Share57.71%
3-Year Operating CF Growth per Share-76.28%
10-Year Net Income Growth per Share-2449.50%
5-Year Net Income Growth per Share-2449.50%
3-Year Net Income Growth per Share-92.98%
10-Year Shareholders Equity Growth per Share1031.53%
5-Year Shareholders Equity Growth per Share1031.53%
3-Year Shareholders Equity Growth per Share287.32%
Receivables Growth10.94%
Inventory Growth-7.52%
Asset Growth-8.38%
Book Value per Share Growth-13.52%
Debt Growth86.82%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 188,826,957, captures the company's total value, considering both debt and equity. Income quality, 0.89, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 46.85%, indicates the value of non-physical assets, and capex to operating cash flow, 112.53%, measures reinvestment capability.

Enterprise Value188,826,957
Income Quality0.89
Intangibles to Total Assets46.85%
Capex to Operating Cash Flow112.53%
Capex to Revenue-134.32%
Capex to Depreciation-842.25%
Graham Number20.28
Return on Tangible Assets-28.52%
Graham Net Net2.75
Working Capital93,509,324
Tangible Asset Value117,898,705
Net Current Asset Value91,460,594
Average Receivables19,735,940
Average Payables18,314,699
Average Inventory34,127,975
Days Sales Outstanding225
Days Payables Outstanding81
Days of Inventory On Hand145

Valuation Ratios

The price to sales ratio, 33.83, provides a perspective on valuation in relation to sales.

Price to Sales Ratio33.83
Enterprise Value Multiple280.61
Price to Tangible Book Ratio1.03
Enterprise Value to Sales5.59
Enterprise Value Over EBITDA-4.37
EV to Operating Cash Flow-4.69
Earnings Yield-17.09%
Free Cash Flow Yield-32.14%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Arctic Bioscience AS (ABS.OL) on the OSL in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 0.000 in 2024.

What is the ticker symbol of Arctic Bioscience AS stock?

The ticker symbol of Arctic Bioscience AS stock is ABS.OL.

What is company IPO date?

IPO date of Arctic Bioscience AS is 2021-02-24.

What is company current share price?

Current share price is 10.000 NOK.

What is stock market cap today?

The market cap of stock today is 253696000.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 17.